Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimidex and Zoladex in Premenopausal Advanced Breast Cancer
NCT00235937Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2001
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in breast cancer, sponsored by AstraZeneca. Primary endpoint: Objective Response Rate. Started Dec 2001; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00235937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00235937.